IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

KKR buys stake in Indian firm Gland Pharma for $200 million

8:44 AM MST | December 2, 2013 | Natasha Alperowicz

KKR, a leading global investment firm, says it will acquire a minority stake in Gland Pharma (Hyderabad, India), a leading Indian pure-play generic injectables pharmaceutical products company focusing mainly on the US market. KKR will pay approximately $200 million for the entire stake held by Evolvence India Life Sciences Fund, an existing private equity investor in Gland. The transaction, which will give KKR approximately 35% in Gland, is subject to regulatory approvals and other customary closing conditions.    Gland, established in 1978, develops...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa